Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

Returns on capital

Elicio Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-2418.8%

avg -237.2%

ROIC

-201.0%

avg -69.9%

ROA

-153.0%

avg -119.7%

Analysis

ROA is currently the strongest return metric at -153.0% versus its period average of -119.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Robert T. Connelly

Chief Executive Officer, President & DirectorUSD 980.7K66——

Christopher Haqq

Executive Vice President, Head of Research & Development and Chief Medical OfficerUSD 750K6064.64K0.34%

Preetam Shah

Chief Strategy & Financial Officer and TreasurerUSD 687.08K5360.83K0.32%

Peter DeMuth

Chief Scientific OfficerUSD 648.6K3952.83K0.28%

Allen Richard Nissenson FACP

Founder & Independent DirectorUSD 52.5K79——

Esther Welkowsky

Senior Vice President of Clinical Development————

Megan C. Filoon

General Counsel, Secretary & Compliance Officer————

Darrell J. Irvine

Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board————

Joy Seymour

Vice President & Head of Regulatory Affairs————

Marc J. Wolfgang

Chief Technology Officer————

Compensation is shown in the reported currency; data updated Aug 29, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Elicio Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ELTX's management, answered from reported figures.

Who manages ELTX?

Elicio Therapeutics, Inc. (ELTX) lists 10 active executives. The top listed executive is Allen Richard Nissenson FACP, Founder & Independent Director.

Are ELTX insiders buying or selling?

Recent insider activity shows net buying of $38.43M.